Cargando…
Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
Objectives: To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Methods: Retrospective observational cohort study, single-center tertiary Intensive Care Uni...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624865/ https://www.ncbi.nlm.nih.gov/pubmed/34835518 http://dx.doi.org/10.3390/microorganisms9112393 |
_version_ | 1784606278627098624 |
---|---|
author | Ego, Amédée Peluso, Lorenzo Gorham, Julie Diosdado, Alberto Restuccia, Giovanni Creteur, Jacques Taccone, Fabio Silvio |
author_facet | Ego, Amédée Peluso, Lorenzo Gorham, Julie Diosdado, Alberto Restuccia, Giovanni Creteur, Jacques Taccone, Fabio Silvio |
author_sort | Ego, Amédée |
collection | PubMed |
description | Objectives: To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Methods: Retrospective observational cohort study, single-center tertiary Intensive Care Unit. COVID-19 patients with ARDS (March–May 2020) and non-COVID ARDS patients (2017–2020) on mechanical ventilation and receiving sedation for at least 48 h. Results: A total of 39 patients met the inclusion criteria in each group, with similar demographics at baseline. COVID-19 patients had a longer duration of MV (median 22 (IQRs 16–29) vs. 9 (6–18) days; p < 0.01), of sedatives administration (18 (11–22) vs. 5 (4–9) days; p < 0.01) and NMBA therapy (12 (9–16) vs. 3 (2–7) days; p < 0.01). During the first 7 days of sedation, compared to non-COVID patients, COVID patients received more frequently a combination of multiple sedative drugs (76.9% vs. 28.2%; p < 0.01) and a higher NMBA regimen (cisatracurium: 3.0 (2.1–3.7) vs. 1.3 (0.9–1.9) mg/kg/day; p < 0.01). Conclusions: The duration and consumption of sedatives and NMBA was significantly increased in patients with COVID-19 related ARDS than in non-COVID ARDS. Different sedation strategies and protocols might be needed in COVID-19 patients with ARDS, with potential implications on long-term complications and drugs availability. |
format | Online Article Text |
id | pubmed-8624865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86248652021-11-27 Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS Ego, Amédée Peluso, Lorenzo Gorham, Julie Diosdado, Alberto Restuccia, Giovanni Creteur, Jacques Taccone, Fabio Silvio Microorganisms Article Objectives: To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Methods: Retrospective observational cohort study, single-center tertiary Intensive Care Unit. COVID-19 patients with ARDS (March–May 2020) and non-COVID ARDS patients (2017–2020) on mechanical ventilation and receiving sedation for at least 48 h. Results: A total of 39 patients met the inclusion criteria in each group, with similar demographics at baseline. COVID-19 patients had a longer duration of MV (median 22 (IQRs 16–29) vs. 9 (6–18) days; p < 0.01), of sedatives administration (18 (11–22) vs. 5 (4–9) days; p < 0.01) and NMBA therapy (12 (9–16) vs. 3 (2–7) days; p < 0.01). During the first 7 days of sedation, compared to non-COVID patients, COVID patients received more frequently a combination of multiple sedative drugs (76.9% vs. 28.2%; p < 0.01) and a higher NMBA regimen (cisatracurium: 3.0 (2.1–3.7) vs. 1.3 (0.9–1.9) mg/kg/day; p < 0.01). Conclusions: The duration and consumption of sedatives and NMBA was significantly increased in patients with COVID-19 related ARDS than in non-COVID ARDS. Different sedation strategies and protocols might be needed in COVID-19 patients with ARDS, with potential implications on long-term complications and drugs availability. MDPI 2021-11-20 /pmc/articles/PMC8624865/ /pubmed/34835518 http://dx.doi.org/10.3390/microorganisms9112393 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ego, Amédée Peluso, Lorenzo Gorham, Julie Diosdado, Alberto Restuccia, Giovanni Creteur, Jacques Taccone, Fabio Silvio Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS |
title | Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS |
title_full | Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS |
title_fullStr | Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS |
title_full_unstemmed | Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS |
title_short | Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS |
title_sort | use of sedatives and neuromuscular-blocking agents in mechanically ventilated patients with covid-19 ards |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624865/ https://www.ncbi.nlm.nih.gov/pubmed/34835518 http://dx.doi.org/10.3390/microorganisms9112393 |
work_keys_str_mv | AT egoamedee useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT pelusolorenzo useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT gorhamjulie useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT diosdadoalberto useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT restucciagiovanni useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT creteurjacques useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT tacconefabiosilvio useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards |